# Research

## Our Research Focus

The Joe Yeong Laboratory is dedicated to advancing the field of spatial omics through innovative research and computational approaches.

### Current Research Areas

#### Spatial Transcriptomics

We develop and apply cutting-edge spatial transcriptomics technologies to understand gene expression patterns in their native tissue context.

#### Multi-omics Integration

Our laboratory specializes in integrating multiple omics datasets to provide comprehensive insights into biological systems.

#### Computational Biology

We develop novel computational methods and algorithms for analyzing complex spatial omics data.

#### Biomarker Discovery

Through our research, we identify and validate biomarkers for various diseases and biological processes.

### Research Projects

*[Specific research projects to be detailed]*

### Methodologies

- Single-cell and spatial transcriptomics
- Computational data analysis
- Machine learning applications
- Statistical modeling
- Bioinformatics pipeline development

### Collaborations

We actively collaborate with researchers and institutions worldwide to advance our understanding of spatial biology.

### Funding

Our research is supported by various funding agencies and institutions (Awarded >20M since 2017). 
Awarded project funding includes: 

- NMRC LCG - Conquering Lung cancer Across all stages with Research and InnovatiON (CLARION)(Role: Theme PI)
- NMRC LCG - Singapore lYMPHoma translatiONal studY (SYMPHONY) 2.0 (Role: Theme PI)
- NMRC CIA - Developing an AI deep learning-based paThology solution for predictive biomArker predictioN for oncoloGy clinical trials allocation (DATANG) (Role: Lead PI)
- NRF CRP - NICHES: NIChe-driven immunoevasion and metastasis in High-risk cancer subtypes for Effective Stratification (Role: Team PI)
- NIH R01 - The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharygeal carcinoma (Role: Co-PI)
- MOH CSA - Elucidating ImmuNe ReprogrammIng in NasopharynGeal CarcinoMA (ENIGMA) (Role: Co-PI)
- A*STAR IAF-ICP - Systematic single-cell resolution analyses of the circulating celel milieu in cancer patients (Role: Lead  PI)
- A*STAR IAF-ICP - To Develop an AI-powered, Scalable and High-throughput Imaging-based Assay for Identification of Immunogenic Tumour-associated Antigens for Cancer Vaccines (Role: Lead-PI)

---

## Publications

### Recent Publications

1. Spatial immune scoring system predicts hepatocellular carcinoma recurrence. Nature
2. Mixture of experts in large language models. arXiv preprint
3. A Foundation Model for Spatial Proteomics. arXiv preprint
4. The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then? Cancer Personalized Treatment
5. An integrated approach for analyzing spatially resolved multi-omics datasets from the same tissue section. Frontiers in Molecular Biosciences
6. Asia's emergence in cancer immunotherapy: challenges and opportunities. Journal for ImmunoTherapy of Cancer
7. Training immunophenotyping deep learning models with the same-section ground truth cell label derivation method improves virtual staining accuracy. Response/Resistance to PD-1 Axis Inhibitors
8. Advancing Tissue Biology Research With Weave Software For Spatial Multi-Omics. MDPI
9. H&E 2.0: deep learning prediction of lung cancer biomarkers pan-cytokeratin and PD-L1 using a dual model framework. Journal for ImmunoTherapy of Cancer
10. A Novel Manual "Centrifuged-Enhanced" Cytosmear Technique for Improving Hypocellular Cytology in the Diagnosis of Vitreoretinal Lymphoma. Translational Vision Science & Technology
11. Charting New Paths in Cancer Research: Insights from the Frontiers in Cancer Science Conference 2024. Cancer Research
12. Achieving Trustworthy Real-Time Decision Support Systems with Low-Latency Interpretable AI Models. arXiv preprint
13. Developing cell-based therapies for pancreatic ductal adenocarcinoma. The Journal of Clinical Investigation
14. Single‐Cell Profiling: Any Scale, Any Size, All at Once. Advanced Science

### All Publications

#### 2025

1. Spatial immune scoring system predicts hepatocellular carcinoma recurrence
2. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
3. Spatially resolved tumor ecosystems and cell states in gastric adenocarcinoma progression and evolution
4. Nonuniversality of inflammaging across human populations
5. A Foundation Model for Spatial Proteomics
6. Mixture of experts in large language models
7. Tumor immune microenvironment delineates progression trajectories of distinct nasopharyngeal carcinoma phenotypes
8. Tumor-immune partitioning and clustering algorithm for identifying tumor-immune cell spatial interaction signatures within the tumor microenvironment
9. The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?
10. An integrated approach for analyzing spatially resolved multi-omics datasets from the same tissue section
11. Spatial heterogeneity, stromal phenotypes, and therapeutic vulnerabilities in colorectal cancer peritoneal metastasis
12. Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study.
13. Asia's emergence in cancer immunotherapy: challenges and opportunities
14. Single cell AI-prediction of protein biomarker on novel whole slide unstained blood smear images
15. EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer
16. Manufacturing characteristics and early outcomes of a tandem aCD22-aCD19 CAR-T therapy for childhood and adult relapsed/refractory acute precursor B lymphoblastic leukemia
17. Training immunophenotyping deep learning models with the same-section ground
18. Advancing Tissue Biology Research With Weave Software For Spatial Multi-Omics
19. 1089 H&E 2.0: deep learning prediction of lung cancer biomarkers pan-cytokeratin and PD-L1 using a dual model framework
20. 1106 H&E 3.0: Pix2Pix-based virtual haematoxylin and eosin staining from greyscale images with feature comparison
21. Multiomic signatures of durable response in a Phase I/II trial of tandem aCD22-aCD19 CAR-T therapy for relapsed B-lineage acute lymphoblastic leukaemia
22. A Novel Manual "Centrifuged-Enhanced" Cytosmear Technique for Improving Hypocellular Cytology in the Diagnosis of Vitreoretinal Lymphoma
23. Author Correction: Spatial immune scoring system predicts hepatocellular carcinoma recurrence
24. Charting New Paths in Cancer Research: Insights from the Frontiers in Cancer Science Conference 2024
25. Achieving Trustworthy Real-Time Decision Support Systems with Low-Latency Interpretable AI Models
26. Using longitudinal spatial-omics to demonstrate in-situ Epstein-Barr virus reduction in responders to immunotherapy treated nasopharyngeal cancer.
27. Lung cancer risk prediction in Asian populations: A study of immune signatures from the Singapore Longitudinal Ageing Studies
28. Longitudinal blood-based immuno-monitoring reveals distinct immune profiles in colorectal cancer patients with divergent responses to first-line systemic therapy
29. The aged tumor microenvironment limits T cell control of breast cancer
30. Decoding cancer prevention: Exercise, dark proteome signatures, and spatial proteomics
31. Developing cell-based therapies for pancreatic ductal adenocarcinoma
32. Single‐Cell Profiling: Any Scale, Any Size, All at Once
33. Spatial Technologies: A Game Changer for Studying the Tumor Microenvironment

#### 2024

1. Phase II DORA study of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer
2. Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies
3. Bioengineered hydrogels enhance ex vivo preservation of patient-derived tumor explants for drug evaluation
4. Spatial omics techniques and data analysis for cancer immunotherapy applications
5. Platelet TLR7 is essential for the formation of platelet–neutrophil complexes and low-density neutrophils in lupus nephritis
6. The prognostic value of CD39 as a marker of tumor-specific T cells in triple-negative breast cancer in Asian women
7. Advancements and applications of AI technologies in pathology: a scoping review
8. Training immunophenotyping deep learning models with the same-section ground truth cell label derivation method improves virtual staining accuracy
9. Regulation of non‐canonical proteins from diverse origins through the nonsense‐mediated mRNA decay pathway
10. Bioactive polyethylene-coated nonwovens for wound healing application
11. The interplay between natural killer cells and pancreatic stellate cells in pancreatic ductal adenocarcinoma
12. Inflammasome-Driven Fatal Acute-on-Chronic Liver Failure Triggered by Mild COVID-19
13. Comprehensive molecular characterization of collecting duct carcinoma for therapeutic vulnerability
14. Deciphering MARCH5's impact on multiple myeloma: insights into autophagy regulation and AKT-FOXO3 signaling
15. 831 Introducing a software package for integrated visualization and data analysis of spatial omics datasets
16. 1250 H&E-based cell prediction multi-classification models to capture morphologically distinct subpopulations of CD8+ T cells
17. A PHASE 1 DOSE ESCALATION STUDY OF EBC-129, A FIRST-IN CLASS, ANTI N-GLYCOSYLATED CEACAM5 & CEACAM6 ANTIBODY-DRUG CONJUGATE (ADC) IN PATIENTS WITH SOLID TUMORS
18. A phase Ib/II study of pacritinib, an interleukin 1 receptor associated kinase 1 (IRAK1) inhibitor, in patients (pts) with solid tumors harboring the 1q21.3 copy number amplification (CNA).
19. Association between CH mutation in TET2and solid cancer in elderly Asian women.
20. A universal pipeline to combine spatial transcriptomics, proteomics, and diagnostic H&E assays on a single tissue section to study tissue microenvironment.
21. Advances in AI-Enhanced Biomedical Imaging for Cancer Immunology
22. Automated Hyperplex Protein Staining and Imaging System on Lung Adenocarcinoma Tissue using off-the-shelf Primary Antibodies
23. INFLAMM-AGING IS NOT A UNIVERSAL AGING MECHANISM ACROSS DIVERSE HUMAN POPULATIONS
24. Aristolochic acid‐related renal cell carcinoma exhibits a distinct tumor‐immune microenvironment favoring response to immune checkpoint blockade
25. Proliferative CD8 T-Cells: A Novel Immune Microenvironmental Determinant of Outcomes in Multiple Myeloma with Translocation (4; 14)
26. 1249 Improving CD8+ cell detection in spatial immunology with generalizable H&E deep learning models trained on diverse clinical scanners
27. 119 Auto-imaging cytometry on the slide (ICOS) for quality control of CAR-T products
28. 1348 Evaluation of a cancer vaccine targeting MAGED4B in preventing oral cancer development from oral epithelial dysplasia
29. 1213 Development and multiplexing of virtual immuno-oncology biomarkers for enhanced research and discovery
30. 1221 Deciphering cellular features: StyleGAN for enhancing H&E cell classification
31. P3. 03I. 06 Neoadjuvant Gefitinib in EGFR Mutated NSCLC (a Phase 2 Window-Of-Opportunity Study): Deep Genomic and Transcriptomic Analysis
32. Effect of tumor-immune microenvironment (TIME) on disparate ascending (A) and descending (D) subtypes of nasopharyngeal carcinoma (NPC).
33. Abstract P69: Immune Landscape of BRCA1/2 -mutated Breast and Ovarian Cancers in an Asian Cohort
34. Abstract LT09: Integrative Multi-Omics Enhancer Activity Profiling Identifies Therapeutic Vulnerabilities in Cholangiocarcinoma of Different Etiologies
35. Abstract LB252: iCellSight: An interactive tool for analyzing and visualizing in-situ high-plex cellular protein data
36. Prognostic Impact of Tertiary Lymphoid Structures in Triple-Negative Breast Cancer
37. Spatial Analysis of the Tumor Microenvironment and Gene Expression in LSD1-expressing Triple-negative Breast Cancer (TNBC)
38. H&E2. 0—Harnessing Artificial Intelligence to Enhance Biomarker Prediction Using Hematoxylin and Eosin-Stained Image
39. A case of metastatic lymphoepithelial carcinoma of parotid gland identified on 68gallium DOTA-[Tyr3] octreotate PET CT

#### 2023

1. Probabilistic embedding, clustering, and alignment for integrating spatial transcriptomics data with PRECAST
2. Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
3. Application of artificial intelligence to in vitro tumor modeling and characterization of the tumor microenvironment
4. PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma
5. Spatial transcriptomics reveal topological immune landscapes of Asian head and neck angiosarcoma
6. The promise and challenge of spatial omics in dissecting tumour microenvironment and the role of AI
7. 3D printed bioactive PLGA dermal scaffold for burn wound treatment
8. Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma
9. Cylindrin from Imperata cylindrica inhibits M2 macrophage formation and attenuates renal fibrosis by downregulating the LXR-α/PI3K/AKT pathway
10. Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma
11. CD38 marks the exhausted CD8+ tissue-resident memory T cells in hepatocellular carcinoma
12. Conditional knockout of hypoxia-inducible factor 1-alpha in tumor-infiltrating neutrophils protects against pancreatic ductal adenocarcinoma
13. Transcriptomic analyses of localized prostate cancers of East Asian and North American men reveal race‐specific luminal‐basal and microenvironmental differences
14. Early triple-negative breast cancers in a Singapore cohort exhibit high PIK3CA mutation rates associated with low PD-L1 expression
15. ProFAST: a fast and scalable factor analysis for spatially aware dimension reduction of multi-section spatial transcriptomics data
16. 1311 H&e 2.0: deep learning-enabled identification of tumor-specific cd39+ cd8+ t cells in marker-free images for predicting immunotherapy response
17. Bioactive polyethylene synthesized by ring opening metathesis polymerization for potential orthopaedic applications
18. 1282 H&E 2.0 virtual staining of CD3+ T cells: improving cell labeling for precise model training
19. 1279 H&e-2.0: an extended application of st-net to liver cancer and its generalizability
20. 1512 Single-cell resolution spatial transcriptomics detection of pathogens followed by studying the immune milieu: using virus-associated cancers from different organs as paradigm
21. Author Correction: Probabilistic embedding, clustering, and alignment for integrating spatial transcriptomics data with PRECAST
22. Novel neoantigen peptides and tumor regression in the MC38 colorectal cancer model.
23. Association of Claudin-1 overexpression with immune exclusion in nasopharyngeal carcinoma and its potential as a novel therapeutic target.
24. Spatial Technologies: A Game Changer for Studying the Tumor Microenvironment
25. Imaging and treatment with 68Gallium and 177Lutetium-DOTATATE in a rare SSTR2 and ESWR1-CREM fusion positive undifferentiated round cell tumour of the lung.

26. Abstract A052: Comprehensive EBV-specific T cell profiling and multi-omics analysis of nasopharyngeal carcinoma CD8 T cells reveals novel cancer-associated phenotype
27. Assessment of an AI virtual staining model performance across same and serial tissue sections using CD3+ T cell ground truth
28. 355O Artificial intelligence-powered spatial analysis of tumor microenvironment (TME) in nasopharyngeal carcinoma (NPC) patients treated with immune checkpoint inhibitors (ICI)
29. 167 Increased programmed cell death 1 ligand 2 (PD-L2) protein and transcript levels in triple negative breast cancer patients improve prognostic value through immune pathway activation.
30. 431 LongiBloodImmunoM: longitudinal blood-based immunomonitoring of CAR-T cell therapy patients for predictive biomarkers
31. 200 DETECT–Cost-effective, high-throughput enrichment of low molecular weight proteins in serum proteomics–insights from a CAR-T therapy trial
32. 222-D Automated hyperplex staining and imaging system on various cancer tissues using off the shelf antibodies
33. The promise and challenge of spatial omics in dissecting tumour microenvironment and the role of AI
34. Regulation of Non-Canonical Proteins Encoded by Small Open Reading Frames via the Nonsense-Mediated Decay Pathway
35. P833: MARCH5 AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA
36. Abstract 974: Fully customizable multiplex immunofluorescent (mIF) assay as proof-of-concept lab-developed test (LDT) for cancer immunotherapy: Using direct conjugation of antibodies with commercially-available dyes.
37. Prognostic Value of Programmed Cell Death 1 Ligand 2 (PD-L2) Immune Infiltrates and mRNA Expression in Triple-negative Breast Cancer

#### 2022

1. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19
2. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
3. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma
4. Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID
5. Joint dimension reduction and clustering analysis of single-cell RNA-seq and spatial transcriptomics data
6. Hypoxia-regulated carbonic anhydrase IX (CAIX) protein is an independent prognostic indicator in triple negative breast cancer
7. Trajectory of immune evasion and cancer progression in hepatocellular carcinoma
8. Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model
9. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
10. Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer
11. A randomized phase 2 trial of nivolumab versus nivolumab-ipilimumab combination in EGFR-mutant NSCLC
12. Transcriptional analysis highlights three distinct immune profiles of high-risk oral epithelial dysplasia
13. Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non-Small-Cell Lung Cancer
14. Bioactive PCL-peptide and PLA-peptide brush copolymers for bone tissue engineering
15. Soft Tissue Leiomyosarcoma With Microsatellite Instability, High Tumor Mutational Burden, and Programmed Death Ligand-1 Expression Showing Pathologic Complete Response to Pembrolizumab: A Case Report
16. Detection of viable SARS-CoV-2 in deep respiratory specimens despite negative nasopharyngeal SARS-CoV-2 RT-PCR: Occult COVID-19 as an unsuspected cause of pulmonary infiltrates in immunocompromised patients
17. multiplex Immunohistochemistry/Immunofluorescence technique: the potential and promise for clinical application
18. Corrigendum: Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID
19. Human umbilical cord lining-derived epithelial cells: a potential source of non-native epithelial cells that accelerate healing in a porcine cutaneous wound model
20. Reply to: Letter to editor on the article "Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy"
21. Case report: Understanding the impact of persistent tissue-localization of SARS-CoV-2 on immune response activity via spatial transcriptomic analysis of two cancer patients with COVID-19 co-morbidity
22. Comparative genomic analyses between Asian and Caucasian prostate cancers in an 80,829 patient cohort.
23. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.
24. Cancer testis antigens in cancer: Recent developments as cancer biomarkers and therapeutic targets
25. 1304 Dietary patterns associated with increased abundance of Akkermansia muciniphila potentiates anti-PD-L1 immune checkpoint blockade response in triple-negative breast cancer
26. A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects
27. Comparison between non-pulmonary and pulmonary immune responses in a HIV decedent who succumbed to COVID-19
28. 1039 The prognostic value of tumour-specific T cells in Asian TNBC: using CD39+ CD8+ T cells as a surrogate marker
29. 1035 High-dimensional immune profiling of peripheral epstein-barr virus-specific T cells in nasopharyngeal carcinoma
30. Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies
31. Probabilistic embedding and clustering with alignment for spatial transcriptomics data integration with precast
32. SpatialDEG: identification of differentially expressed genes by leveraging spatial information in spatially resolved transcriptomic studies
33. Multiplex Immunohistochemistry/Immunofluorescence Technique: The Potential and Promise for Clinical Application
34. Mass-forming immunoglobulin G4-related disease shows indolent clinical course after surgical resection, clinicopathological analysis of a series of 15 cases
35. 1041 PIK3IP1/TrIP immune regulation on CD8+ T Cells restricts anti-tumor immunity
36. 1288 Spatial transcriptomics-enabled integrated morphology-transcriptome tumor cell phenotyping using machine learning
37. 867 Deciphering of radiotherapy-induced immunomodulation effect synergized with immunotherapy in hepatocellular carcinoma by spatial multi-omics profiling
38. EP16. 03-036 Clinical and Genomic Features of HER2 exon 20 Insertion Mutations in East Asian NSCLC
39. Persistence of SARS-CoV-2 in long COVID-19 patients
40. Immune Response in Myocardial Injury: In Situ Hybridization and Immunohistochemistry Techniques for SARS-CoV-2 Detection in COVID-19 Autopsies (vol 8, 658932)
41. Corrigendum: Immune Response in Myocardial Injury: In Situ Hybridization and Immunohistochemistry Techniques for SARS-CoV-2 Detection in COVID-19 Autopsies
42. Cribriform Pattern Prostate Cancer and Associated Genomic Classifier (GC) Risk Scores in Asian Men

#### 2021

1. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial
2. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma
3. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma
4. Intratumoral CD39+ CD8+ T cells predict response to programmed cell death protein-1 or programmed death ligand-1 blockade in patients with NSCLC
5. SC-MEB: spatial clustering with hidden Markov random field using empirical Bayes
6. Effect of corneal cross-linking versus standard care on keratoconus progression in young patients: the KERALINK randomized controlled trial
7. Pan-cancer analysis of ligand–receptor cross-talk in the tumor microenvironment
8. Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy
9. Immunological hallmarks for clinical response to BCG in bladder cancer
10. Epstein–Barr virus epithelial cancers—A comprehensive understanding to drive novel therapies
11. Integrative profiling of T790M-negative EGFR-mutated NSCLC reveals pervasive lineage transition and therapeutic opportunities
12. Targeting glycolysis in macrophages confers protection against pancreatic ductal adenocarcinoma
13. CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer
14. Biomarkers for precision urothelial carcinoma diagnosis: Current approaches and the application of single-cell technologies
15. Cancer-testis antigens in triple-negative breast cancer: role and potential utility in clinical practice
16. Leveraging advances in immunopathology and artificial intelligence to analyze in vitro tumor models in composition and space
17. Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence
18. Clinical implications of systemic and local immune responses in human angiosarcoma
19. 89 The immune marker LAG-3 increases the predictive value of CD38+ immune cells for survival outcome in immunotherapy-treated hepatocellular carcinoma
20. Immune Response in Myocardial Injury: In Situ Hybridization and Immunohistochemistry Techniques for SARS-CoV-2 Detection in COVID-19 Autopsies
21. 627 ImmunoAtlas: an online public portal for sharing, visualizing, and referencing 
multiplex immunohistochemistry/immunofluorescence (mIHC/IF) images and results for 
immunoncology
22. Intra-Tumoral CD39 (+) CD8 (+) T Cells Predict Response to PD-1/PD-L1 Blockade in Patients With NSCLC
23. 626 Dissecting the spatial heterogeneity of SARS-CoV-2-infected tumour microenvironment reveals a lymphocyte-dominant immune response in a HBV-associated HCC patient with COVID-19 history
24. 911 Immune profiling reveals enrichment of distinct immune signatures in high-risk oral potentially malignant disorders
25. 818 Using deep learning approaches with mIF images to enhance T cell identification for tumor-automation of infiltrating lymphocytes (TILs) scoring on H&E images
26. Improving Precision and Implementation of Immuno-Oncology Biomarkers
27. Approaches for Handling Immunopathological and Clinical Data Using Deep Learning Methodology: Multiplex IHC/IF Data as a Paradigm
28. Randomised phase 2 Study of nivolumab (N) versus nivolumab and ipilimumab (NI) combination in EGFR mutant NSCLC
29. MA13. 08 Genomic and Transcriptomic Features of Distinct Resistance Trajectories in EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
30. Mass Forming Immunoglobulin G4-Related Disease: A Potential Distinct Subtype, Clinicopathological Analysis of A Series of 15 Cases
31. Investigation of a 22-gene genomic classifier (GC) for risk stratification and molecular subtyping in an Asian prostate cancer (PCa) cohort.

#### 2020

1. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy
2. Genomic landscape of lung adenocarcinoma in East Asians
3. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
4. Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma
5. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC
6. Liver fibrosis and CD206+ macrophage accumulation are suppressed by anti-GM-CSF therapy
7. Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers
8. Transcriptional spatial profiling of cancer tissues in the era of immunotherapy: the potential and promise
9. Predictive biomarkers of immune checkpoint inhibition in gastroesophageal cancers
10. IRF-7 mediates type I IFN responses in endotoxin-challenged mice
11. Establishment and characterization of humanized mouse NPC-PDX model for testing immunotherapy
12. A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678
13. Quantitative stain-free imaging and digital profiling of collagen structure reveal diverse survival of triple negative breast cancer patients
14. Higher densities of tumour‐infiltrating lymphocytes and CD4+ T cells predict recurrence and progression of ductal carcinoma in situ of the breast
15. The Virological, Immunological, and Imaging Approaches for COVID-19 Diagnosis and Research
16. Digital spatial profiling application in breast cancer: A user's perspective
17. PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas
18. Characteristics, behaviour and role of biomarkers in metastatic triple-negative breast cancer
19. Partial absence of PD‐1 expression by tumor‐infiltrating EBV‐specific CD8+ T cells in EBV‐driven lymphoepithelioma‐like carcinoma
20. Counting mitoses with digital pathology in breast phyllodes tumors
21. Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: the Singapore experience
22. Residual SARS-CoV-2 viral antigens detected in gastrointestinal and hepatic tissues from two recovered COVID-19 patients
23. Tumor-Immune Partitioning and Clustering (TIPC) algorithm reveals distinct signatures of tumor-immune cell interactions within the tumor microenvironment
24. 218MO comparison of a 22-gene genomic classifier (GC) with NCCN for risk stratification of Asian prostate cancers (PCa)
25. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple negative breast cancer: validation of a translational assay with conventional IHC
26. 475 Incidental finding of colorectal cancer in a COVID-19 patient, followed by deep profiling of SARS-CoV-2-associated immune landscape and tumour microenvironment
27. 825 Deep immune profiling of SARS-CoV-2 associated immune microenvironment in cancer tissues from recovered COVID-19 patients
28. Proliferative and quiescent human gastric cancer stem-like cells are associated with differential chemoresistance and patient mortality
29. Tri-compartment (epithelial, immune, fibroblast) patient-derived models of the tumor microenvironment from an immuno-genomic profiled cohort of early stage colorectal cancers
30. Spatial and multi-omics characterization of the tumor microenvironment in colorectal cancer
31. A prospective observational study of combinatorial abiraterone (AA) and radical radiotherapy (RT) in node-positive (N+) prostate cancer (PCa).
32. Hypoxia-Regulated Carbonic anhydrase IX (CAIX) Protein is an Independent Prognostic Indicator in Triple Negative Breast Cancer
33. Preliminary outcomes of a prospective observational study of combinatorial abiraterone acetate/enzalutamide (AA/Enz) and radical radiotherapy (RT) in nonmetastatic node-positive (N+M0) prostate cancer (PCa)
34. 7. PD-L1 in triple negative breast cancer–optimal testing for therapeutic efficacy
35. Primary platinum resistance and immune exclusion in ovarian carcinomas with high expression of the homologous recombination mediator RAD51

#### 2019

1. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma
2. Prognostic value of CD8+ PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer
3. Expression of CD38 on macrophages predicts improved prognosis in hepatocellular carcinoma
4. Pan-cancer analysis connects tumor matrisome to immune response
5. The roles of CD38 and CD157 in the solid tumor microenvironment and cancer immunotherapy
6. Prognostic role of immune infiltrates in breast ductal carcinoma in situ
7. Comparison between UMAP and t-SNE for multiplex-immunofluorescence derived single-cell data from tissue sections
8. Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence
9. Data-driven inference of crosstalk in the tumor microenvironment
10. CD38 is a good predictor of anti-PD-1 immunotherapy responsiveness in hepatocellular carcinoma
11. Role of tissue resident memory CD8+ T cells in triple negative breast cancer
12. Solar-IHC: Cell-to-cell distances in the tumour immune microenvironment of Hepatocellular Carcinoma has the potential to prognosticate survival
13. Harmony: Integrative tool to analyse and visualise multiplex-immunofluorescence single-cell data
14. Single cellular interrogation of tumor microenvironment enables diagnosis and prognostication of malignancies
15. Chia N, Ong CCH, Lye WK, Putti TC
16. A novel computational OMICS and non-OMICS approach for identifying true pathogenic risk variants for Asian prostate cancer.
17. Partial absence of PD-1 expression by tumor-specific CD8+ T cells in EBV-driven lymphoepithelioma-like carcinoma: a case report
18. Programmed Cell Death 1 Ligand 2 (PD-L2) protein expression is associated with better prognosis in Triple Negative Breast Cancer
19. AI Empowered High-accuracy Prognosis for Triple-Negative Breast Cancer using Quantitative Multiplex Immunofluorescence Images
20. T-Box transcription factors (TBX21) protein expression is associated with better prognosis in Triple Negative Breast Cancer
21. Genomic and immune infiltration differences between MSI and MSS GI tumors.

#### 2018

1. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
2. High densities of tumor-associated plasma cells predict improved prognosis in triple negative breast cancer
3. An automated staining protocol for seven-colour immunofluorescence of human tissue sections for diagnostic and prognostic use
4. Caveolin-1 expression as a prognostic marker in triple negative breast cancers of Asian women
5. An integrated automated multispectral imaging technique that simultaneously detects and quantitates viral RNA and immune cell protein markers in fixed sections from Epstein-Barr virus-related tumours
6. TFE3-expressing epithelioid rich perivascular epithelioid cell neoplasm (PEComa) of the bladder with unusual benign course
7. Using computer assisted image analysis to determine the optimal Ki67 threshold for predicting outcome of invasive breast cancer
8. A phase II open-label, single-centre, non-randomized trial of Y90 transarterial radioembolization in combination with nivolumab in Asian patients with intermediate stage hepatocellular carcinoma: An immunological study of radioembolization in combination with anti-PD1 therapy in HCC.
9. High densities of tumor-associated plasma cells predict improved prognosis in triple negative breast cancer. Front Immunol; 9: 1209
10. Somatostatin receptor 2 expression and clinical significance in pulmonary Lymphoepithelioma-like carcinoma
11. A Phase 2, Open-Label, Single-Center Study of Y90-Radioembolization in Combination With Nivolumab in Asian Patients With Advanced Hepatocellular Carcinoma
12. Abstract 5725: Systematic identification of tumour-specific neoantigens(by whole-genome sequencing) and correlation between tumour neoantigen burden, PD-L1 expression and immune infiltrates in 158 Asian colorectal cancers
13. RNA-Seq analyses of immune cell-type enrichments in 158 Asian colorectal cancers (CRCs).
14. Tumor whole-transcriptome sequencing and multiplex immunohistochemistry of immune cell populations in 158 Asian colorectal cancers
15. Higher Level of VEGF mRNA is Significantly Associated with Poorer Outcome in Triple Negative Breast Cancer
16. Molecular Profiling of Androgen Receptor Positive Triple Negative Breast Cancer
17. PD-L1 As A Prognostic Indicator In Renal Cell Carcinoma: Study Of A Mixed Ethnicity Asian Cohort
18. Prognostic Impact of Tumor-Associated Plasma Cells in Triple Negative Breast Cancer
19. Quantitative Imaging and Deep Profiling of Collagen Structure of Asian Triple Negative Breast Cancer: Novel Perspective for Breast Cancer MicroEnvironment
20. Somatostatin receptor imaging in nasopharyngeal cancer

#### 2017

1. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma
2. Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer
3. Identifying progression predictors of breast ductal carcinoma in situ
4. A functional SNP associated with atopic dermatitis controls cell type-specific methylation of the VSTM1 gene locus
5. Upregulation of hydroxysteroid sulfotransferase 2B1b promotes hepatic oval cell proliferation by modulating oxysterol-induced LXR activation in a mouse model of liver injury
6. A genetic mutation panel for differentiating malignant phyllodes tumour from metaplastic breast carcinoma
7. Gleason grade grouping of prostate cancer is of prognostic value in Asian men
8. Prognostic grade grouping in prostate cancer of Singapore men
9. TFE3-expressing epithelioid rich perivascular epithelioid cell tumour (PECOMA) of the bladder
10. Roles of PD-L1, PD-L2 and PD-1 in Triple Negative Breast Cancers: Perspective from an Asian Cohort
11. Both MHC I and MHC II Pathways Are Associated with Improved Survival in Triple-Negative Breast Cancer
12. Increased FoxP3-Positive Tregs Augur Better Survival and Colocalize with Both CD8 (+) T-cells and CD20 (+) B-cells within the Microenvironment of Triple Negative Breast Cancer

#### 2016

1. PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity
2. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer
3. The role of nuclear factor-kappa B and endoplasmic reticulum stress in hepatitis B viral-induced hepatocellular carcinoma
4. Validation of the prognostic Gleason grade grouping in a large cohort of Asian men with organconfined prostate cancer using a prospectively maintained database
5. Validation of the prognostic Gleason grade grouping in a large cohort of Asian men with organ-confined prostate cancer using a prospectively maintained database: C-OPRO-7257
6. Prognostication of prostate cancer using the D'Amico risk classification can be further enhanced by the number of risk factors involved within the same risk group: C-OPRO-8168
7. CD3+ and FOXP3+ Tumor-Infiltrating Lymphocytes Are Associated with Better Prognosis in Triple Negative Breast Cancers
8. Increased BCL2 Expression Predicts Poor Survival in Triple Negative Breast Cancer Patients

#### 2012

1. Activation and regulation of interferon-β in immune responses

#### 2010

1. Tryptase promotes human monocyte-derived macrophage foam cell formation by suppressing LXRα activation
